Almac Concludes Commercial API Manufacturing Facility Expansion Plans
News Oct 09, 2012
In response to client requirements, Almac’s expansion of their API manufacturing facility at its European Headquarters in Craigavon, UK is near completion, and will be operational by the end of the year.
This upgrade includes installation of two 1,000L reactors and pressure filter dryer, which allows production of GMP Active Pharmaceutical Ingredients (API) up to 150kg batch size.
Almac’s strategy to increase market share in late phase clinical development is reaping rewards, and clients are already seeing the advantages of having one constant manufacturing partner through each phase of clinical development.
“Almac’s investment has further demonstrated our goal of being the outsourcing partner of choice through all stages of clinical development.” stated Denis Geffroy, VP Business Development.
Geffroy continued, “We are delighted to have the scale to share the manufacturing journey with our clients from preclinical phase to full commercialization.”
Clients can also leverage Almac’s API and Drug Product integrated offering where API manufacture and finished drug production is carried out on the same site, ensuring reduction in costs and timelines whilst maintaining scientific continuity.
Almac’s advantage of hosting all facilities on one site have led to the successful technology transfer of small molecule and peptide projects from lab development to large scale manufacture.
For further information, Almac will be exhibiting at the forthcoming CPhI (Booth 10E41) and AAPS (Booth 3027) conferences.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE